Biologics Utilization Impacting US Health Care Spending
Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.
A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.
A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.
Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.
This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.